Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical industry generating and commercializing possible top in class oncology and CNS therapeutics introduced the fact that Japanese Patent Office has released to the Company patent No. 4,934,432, with the title "Quinazoline Derivatives and Therapeutic Utilize Thereof." This particular new patent insures Rexahn's anti-cancer applicant RX-1792 and related substances, as well as a composition for handling anti-proliferative and anti-tumor actions.
Rick Soni, President of Rexahn, mentioned, "We are very happy to achieve this excess patent protection for RX-1792 in Japan, which expands and gives strength to our global intellectual property situation. RX-1792 is continuing to demonstrate interesting anti-proliferative and anti-tumor consequences in preclinical studies, and then we look forward to accelerating its progress."
No comments:
Post a Comment